Strides Pharma Science

This report summarizes the situation with Stelis well. No more money from Strides - separate investors and promotor warrants will put in capital as needed. A large part of the money needed is already raised. The business operates on negative working capital cycles and facilities are forward booked. The only unknown is what happens with the Sputnik stock and the timing of the Arrow receivables. Hopefully no more black swans and the numbers should continue improving and the balance sheet will start looking more healthy.